ClinicalTrials.gg

Program

ZL-82

A development code. Also written as “The high-dose group of ZL-82 tablets”, “The low-dose group of ZL-82 tablets” and “ZL-82 12.5mg”.

Its studies are mostly in Dermatitis, Atopic · Arthritis, Rheumatoid, led by Chengdu Zenitar Biomedical Technology.

Furthest: phase 2, since Apr 27, 20253 company-led studies, 1 open or runningNext primary completion: Dec 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chengdu Zenitar Biomedical Technology31 open or runningphase 2since Apr 27, 2025Sep 19, 2023Dec 30, 2027phase 2 · NCT07193589

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 19, 2023First study: phase 1 study in Arthritis, RheumatoidFirst studyNCT06055023 · 69 enrolled · China
  2. Mar 24, 2024Phase 1 study in Healthy PersonNCT06432738 · 41 enrolled · China
  3. Apr 27, 2025Phase 2 study in Dermatitis, AtopicNCT07193589 · 111 planned · China

Ahead

  1. Dec 30, 2027Primary completion: phase 2 study in Dermatitis, AtopicNCT07193589

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07193589Dermatitis, Atopic · China2RecruitingDec 30, 2027111
NCT06432738Healthy Person · China1CompletedAug 15, 202441
NCT06055023Arthritis, Rheumatoid · China1CompletedJan 28, 202469

How it is read

Names in the registry

  • “The high-dose group of ZL-82 tablets”, 1 entry
  • “The low-dose group of ZL-82 tablets”, 1 entry
  • “ZL-82”, 1 entry
  • “ZL-82 12.5mg”, 1 entry
  • “ZL-82 25mg”, 1 entry

Codes read as this program: ZL82.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.